Rakesh Dadhania & Sudhir Patel: A Visionary Leader Reducing The Complexity Of Clinical Research With Years Of Experience
Rakesh Dadhania & Sudhir Patel
Directors
Engaging with a team of CEO Insights for an exclusive interaction, Sudhir and Rakesh share the story of their journey through the lens of QCR.
Give us brief details about your educational & professional background and how are you leveraging the best of these elements across your pharma & life sciences operations?
Sudhir-I am a graduate in pharmacy, started my professional journey with one of the clinical research organizations based in Ahmedabad, Gujarat. In 2004, the clinical research industry was kind of budding industry. People were more focused on formulation development and the manufacturing of drugs. The first company I worked, made a significant difference in my career where I developed a sound understanding of systems and processes with quality as the first objective.
Rakesh- I am a postgraduate from L M College of Pharmacy. I started my career with dynamic and quality conscious CRO which helped me understand all my Clinical Research fundamentals in the most appropriate manner.
What inspired you to establish Quinary Clinical Research and how has been your journey so far? What were the major challenges that you encountered during your professional journey to date?
Sudhir-Several factors led to the establishment of the Quinary Clinical Research, the main inspiration was the desire to implement our ambitious thoughts. When we started in the year 2016, the government policies were encouraging the new entrepreneurs and startup programs, which had an impact on me and gave me a boost to start my venture. With the help of my family and convincing the people to trust our business, this has been setup.
Rakesh-I feel that when working in a biggerorganization there are limitations to express your potential. This is because there exists governance which you need to follow and was affecting my personal growth, which triggered me into joining our startup.
We are focused on the technology
as our value driven statement of the company is Ethics Redefined With Technology, the adaptation of the techno logy itself is the biggest challenge that we are witnessing. Thankfully, in the covid times, the acceptance in the pharma industry has been more receptive. The bureaucracies or the delay in decision making at Government institutes during Covid-19 are very challenging in the current operations.
As the Co-founder, you believe in the principle of success to a customer focused approach. Please share with us more about this approach.
Sudhir-Dealing with the customers was a different experience for us, as you start understanding what a customer is very closely when you do your own business. Quinary Clinical Research provides services to our customer by a team of well experienced, quality driven and customer focused members. We always tries to ensure that the services we extend should add value to our customers.
Rakesh-Repeat business and cross-reference, these two points come with a lot of commitment to the customer. We have adopted 3Capproach Compliance, Convenience and Cost effectiveness. Being in space of technology solution, we are working with tight regulations, trying to improve compliance with customer's convenience in a cost effective manner.
Brief us about the various products that your organization provides. What new technologies are you planning to leverage to significantly improve the performance of Quinary Clinical along with its discoveries and researches?
Sudhir - We have come up with a decentralized approach for the ethics committee. With the use of this technology, we are simplifying the old paper based process. This simplification of the ethics committee process is helping the all clinical research stakeholders to reduce their study start-up timeline and in turn helping the community/country in making drugs/vaccines available to patients faster. We are the first one in the country to being a comprehensive digital web application for the ethics committee for management of their research submissions. This is useful for research centers as well as academic research too.
Our unique concept of ECMO(Ethics Committee Management Organization) a one stop solution for all needs of the ethics committee in India. We are the first one in the country with such a comprehensive model of ethics committee management.
Rakesh- We went through through the second wave of Covid-19 across India. It is said by scientists that children can be the next target. Accordingly, the vaccine trial for children has started in many hospitals,what needs to be understood is that before you start giving these drugs or vaccines to patients in a group, you need to have approval from the committee which is a multidimensional committee existing at the various research center (Ethics Committees). This committee approval consists of all angles like legal, this is where new regulations come into effect in 2019 where there are a lot of responsibilities on the ethics committees. Our digital EC platform is not only useful for Clinical Trials, but also aids in the academic and different hospitals in helping them in achieving their research objectives.
Where is Quinary Clinical Research positioned in the current pharma & life sciences industry of India and what are your thoughts on the present and future scenarios of this space?
Sudhir-Our innovative concept of digital EC and ethics committee management has helped us to perform consistently even in the tough time of the pandemic. Strict
As the Co-founder, you believe in the principle of success to a customer focused approach. Please share with us more about this approach.
Sudhir-Dealing with the customers was a different experience for us, as you start understanding what a customer is very closely when you do your own business. Quinary Clinical Research provides services to our customer by a team of well experienced, quality driven and customer focused members. We always tries to ensure that the services we extend should add value to our customers.
Rakesh-Repeat business and cross-reference, these two points come with a lot of commitment to the customer. We have adopted 3Capproach Compliance, Convenience and Cost effectiveness. Being in space of technology solution, we are working with tight regulations, trying to improve compliance with customer's convenience in a cost effective manner.
Brief us about the various products that your organization provides. What new technologies are you planning to leverage to significantly improve the performance of Quinary Clinical along with its discoveries and researches?
Sudhir - We have come up with a decentralized approach for the ethics committee. With the use of this technology, we are simplifying the old paper based process. This simplification of the ethics committee process is helping the all clinical research stakeholders to reduce their study start-up timeline and in turn helping the community/country in making drugs/vaccines available to patients faster. We are the first one in the country to being a comprehensive digital web application for the ethics committee for management of their research submissions. This is useful for research centers as well as academic research too.
Our unique concept of ECMO(Ethics Committee Management Organization) a one stop solution for all needs of the ethics committee in India. We are the first one in the country with such a comprehensive model of ethics committee management.
Rakesh- We went through through the second wave of Covid-19 across India. It is said by scientists that children can be the next target. Accordingly, the vaccine trial for children has started in many hospitals,what needs to be understood is that before you start giving these drugs or vaccines to patients in a group, you need to have approval from the committee which is a multidimensional committee existing at the various research center (Ethics Committees). This committee approval consists of all angles like legal, this is where new regulations come into effect in 2019 where there are a lot of responsibilities on the ethics committees. Our digital EC platform is not only useful for Clinical Trials, but also aids in the academic and different hospitals in helping them in achieving their research objectives.
Where is Quinary Clinical Research positioned in the current pharma & life sciences industry of India and what are your thoughts on the present and future scenarios of this space?
Sudhir-Our innovative concept of digital EC and ethics committee management has helped us to perform consistently even in the tough time of the pandemic. Strict
lockdown had an immediate impact on ongoing clinical studies. This was not enough, the pharma companies & CROs wanted to kick start their covid related clinical development while researchers were looking for their research to be in an expedited manner. Our digital EC concept has played an incredible role to expedite their research with the use of our digital proprietary platform, eIRB & eIEC. Especially in India, the conven tional methods of EC submission, review and approval are mostly paper based and many manual interventions. This has been managed by digital EC without any compromise to compliance and quality.
Rakesh- By 2025, the Indian clinical research market is expected to grow at a CAGR of 8.7 percent and be worth $3.1 billion. This is a huge opportunity for India in the global arena of clinical research. The dimensions of the clinical research is huge potential for Academic Research and Startups with newer devices or prototypes designs. With NDCT Rules 2019, well defined roles and responsi bilities of ECs,all these stake holders will need extensive support from EC tor their research projects.
Sudhir Patel, Director, Quinary Clinical Research
If you see the research that happened before COVID and after COVID (the difference within the last 15 months), there is a significant change with the usage of technology and the concept of decentralization.
Do you participate in any mentorship programs or give keynote speeches in conferences & seminars? Do you have any advice for the leaders in the Clinical Trial segment of India?
We are participating in several confe rences of annual levels, and even in many training sessions. We have evolved as an exclusive trainer for Ethics Committee for both Academic as well as for Clinical Trials. In the last four years, we have conducted more than 55 exclusive EC trainings. This is one of the services as well as contribution.
Rakesh - The advice is to take calculative decisions but do not overthink, be action oriented, hard working and always believe in yourself. While Sudhir likes to actively take part in Social Services and listen to motivational speech, I engage myself with Yoga and Exercises. My favorite book is 'Seven Hobbits of Highly Effective People' by Steven Covey.
Sudhir Patel, Director, Quinary Clinical Research
Sudhir Patel formally started his career as a clinical research professional and went on to become an entrepreneur. He holds 16+ years of experience in core clinical operation. His last assignment was with Navitas Life sciences as Senior Project Manager in Clinical Trials. At Quinary Clinical Research in his role of Director,he is responsible for operations.
Rakesh Dadhania, Director, Quinary Clinical Research
Rakesh has a blend of experience working with CROs and Sponsor for 18+ years. He has managed team of 45+ while working as Head of Clinical Operations. His last assignment was with Dr. Reddy's Lab as Associate Director at Biologics. At Quinary Clinical Research, in his role of Director, he is responsible mainly for business development and collaborative expansion.
Rakesh- By 2025, the Indian clinical research market is expected to grow at a CAGR of 8.7 percent and be worth $3.1 billion. This is a huge opportunity for India in the global arena of clinical research. The dimensions of the clinical research is huge potential for Academic Research and Startups with newer devices or prototypes designs. With NDCT Rules 2019, well defined roles and responsi bilities of ECs,all these stake holders will need extensive support from EC tor their research projects.
Sudhir Patel, Director, Quinary Clinical Research
If you see the research that happened before COVID and after COVID (the difference within the last 15 months), there is a significant change with the usage of technology and the concept of decentralization.
Do you participate in any mentorship programs or give keynote speeches in conferences & seminars? Do you have any advice for the leaders in the Clinical Trial segment of India?
We are participating in several confe rences of annual levels, and even in many training sessions. We have evolved as an exclusive trainer for Ethics Committee for both Academic as well as for Clinical Trials. In the last four years, we have conducted more than 55 exclusive EC trainings. This is one of the services as well as contribution.
Rakesh - The advice is to take calculative decisions but do not overthink, be action oriented, hard working and always believe in yourself. While Sudhir likes to actively take part in Social Services and listen to motivational speech, I engage myself with Yoga and Exercises. My favorite book is 'Seven Hobbits of Highly Effective People' by Steven Covey.
Sudhir Patel, Director, Quinary Clinical Research
Sudhir Patel formally started his career as a clinical research professional and went on to become an entrepreneur. He holds 16+ years of experience in core clinical operation. His last assignment was with Navitas Life sciences as Senior Project Manager in Clinical Trials. At Quinary Clinical Research in his role of Director,he is responsible for operations.
Rakesh Dadhania, Director, Quinary Clinical Research
Rakesh has a blend of experience working with CROs and Sponsor for 18+ years. He has managed team of 45+ while working as Head of Clinical Operations. His last assignment was with Dr. Reddy's Lab as Associate Director at Biologics. At Quinary Clinical Research, in his role of Director, he is responsible mainly for business development and collaborative expansion.